Form 4: Exelixis SVP Sells Shares Under 10b5-1 Plan

Sentiment:

Insider Transaction Report 18 February 2026 8:48 PM

Exelixis's SVP and General Counsel, Brenda Hefti, reported the sale of 18,669 shares of common stock and the withholding of 5,430 shares for tax obligations.

Worse than expectedThe filing indicates a significant sale of shares by a senior executive, Brenda Hefti, SVP and General Counsel. While conducted under a Rule 10b5-1 plan, insider selling can be interpreted by the market as a less positive signal compared to insider buying, potentially suggesting that the insider sees less upside in the near term or is diversifying their portfolio.

Summary

Brenda Hefti, SVP and General Counsel of Exelixis, Inc. (EXEL), reported changes in her beneficial ownership.
On February 15, 2026, 5,430 shares of common stock were withheld by Exelixis to satisfy tax obligations related to the vesting of performance-based restricted stock units (RSUs) awarded on March 4, 2022, with performance certified on January 16, 2025. The price per share for this transaction was $43.92.
On February 18, 2026, 18,669 shares of common stock were sold at a weighted average price of $44.01 per share, with prices ranging from $43.32 to $44.49.
These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Hefti on November 19, 2025.
Following these transactions, Ms. Hefti directly owns 96,512 shares of common stock.
Her beneficial ownership also includes 95,956 shares of common stock to be issued upon vesting of restricted stock units (RSUs) and performance stock units (PSUs) granted on March 31, 2025, and 5,527 shares indirectly held through the Exelixis, Inc. 401(k) Plan as of February 13, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a slightly negative sentiment. While the sales were pre-planned under a 10b5-1 plan, the disposition of a notable number of shares by a senior executive is generally not a strong positive indicator for investors, even if it's for personal financial management.

Negatives

A senior executive selling a significant number of shares, even under a pre-arranged plan, can sometimes be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify personal holdings.

Risks

Investor sentiment risk: Insider selling, even when pre-planned, can sometimes lead to negative market perception or speculation, potentially impacting the company's stock price in the short term.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by senior executives, are routinely monitored by investors in the biotechnology and pharmaceutical sectors. While sales under a Rule 10b5-1 plan are pre-scheduled and often for personal financial planning, they can still influence market perception, especially if they are substantial or occur during periods of significant company news.

Stakeholder Impact

Shareholders: May interpret the insider selling as a signal, potentially influencing their investment decisions or market sentiment towards EXEL stock.

Key Dates

Date	Description
March 4, 2022	Award date for performance-based restricted stock units (RSUs).
January 16, 2025	Compensation Committee certified performance criteria for performance-based RSUs.
March 31, 2025	Grant date for One-Time Award PSUs and RSUs.
November 19, 2025	Adoption date of the Rule 10b5-1 trading plan by Brenda Hefti.
February 13, 2026	Date of the Exelixis, Inc. 401(k) Plan statement.
February 15, 2026	Transaction date for shares withheld to satisfy tax obligations.
February 18, 2026	Transaction date for the sale of shares under the Rule 10b5-1 plan.
February 18, 2026	Signature date of the Form 4 filing.

Recommendation

hold

The filing details insider selling by a senior executive, which, while pre-planned, does not provide a strong positive catalyst for the stock. Without additional fundamental company news, a 'hold' recommendation is appropriate as this transaction alone does not warrant a 'buy' or 'sell' based on the limited information provided in a Form 4.

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1 Plan, Restricted Stock Units, Performance Stock Units, Executive Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.